General Practice Doctors in West Lafayette, IN Accepting Medicare

8 General Practice doctors found. Showing 1 - 8

Dr. Ruth S Oconnor, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

Dr. Jean N Perrin, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

Dr. Edward J Hoskins, MD RHD General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

Dr. Sarah A Sayger, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

Dr. Charles W Hewson, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

Dr. Balazs I Hatvani, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

Dr. Ruth C Osborne, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

Dr. Alayne K Sundstrom, DO General Practice Medicare: Not Enrolled in Medicare Practice Location: 601 Stadium Mall Dr, West Lafayette, IN 47907 Phone: 765-494-1700    Fax: 765-496-1227

News Archive

Chemotherapy improves survival for patients with SCLC and LCNEC

Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with limited stage small-cell lung cancer who were treated with perioperative chemotherapy and surgery had better overall survival outcomes than patients treated with surgery alone.

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

New research sheds light on how fruit flies sense foods

Some people love avocados. Others hate them. For many of the latter, the fruit's texture is the source of their intense dislike. What gives?

OU researchers awarded NASA grant to better understand emerging infectious disease threats

An interdisciplinary team of researchers at the University of Oklahoma has been awarded a $730,000 grant from NASA to better understand emerging infectious disease threats in the region of Central Asia, including the 2019 novel coronavirus that is spreading from China.

Read more Medical News

› Verified 6 days ago